suggest
potenti
therapeut
agent
sar
particular
inhibitor
viral
entri
compris
therapeut
peptid
base
recent
launch
antihiv
drug
enfuvirtid
could
repres
one
direct
rout
genom
sequenc
discoveri
antivir
drug
sever
acut
respiratori
syndrom
sar
pulmonari
infect
identifi
multipl
outbreak
around
world
emerg
initi
guangdong
provinc
china
novemb
number
report
case
increas
exponenti
reach
result
death
august
websit
syndrom
caus
previous
unknown
viru
sarsassoci
coronaviru
sarscov
global
sar
outbreak
contain
mainli
owe
strict
patient
isol
aggress
contain
infect
region
viru
potenti
reappear
concern
support
studi
report
cyclic
pattern
humaninfect
coronavirus
attack
mainli
winter
sometim
skip
year
exampl
relat
human
coronaviru
break
everi
two
four
year
date
antivir
drug
half
develop
past
year
treat
singl
viru
develop
antivir
drug
gain
advanc
molecular
structur
biolog
coupl
advanc
medicin
chemistri
industri
drug
discoveri
process
sar
epidem
emphas
need
develop
drug
emerg
viral
infect
quickli
demonstr
usag
genom
technolog
antivir
research
past
two
decad
biolog
becom
informationdriven
scienc
result
emerg
genom
technolog
expans
internet
allow
analysi
genom
databas
everi
research
desktop
advanc
genom
technolog
led
rapid
sequenc
sarscov
first
time
histori
sequenc
genom
infect
agent
preced
understand
basic
biolog
etiolog
arm
genom
inform
research
group
around
world
suggest
multidisciplinari
approach
attain
antisar
drug
gener
physician
tri
reliev
symptom
mainli
modul
part
immun
system
vaccinologist
began
long
process
develop
vaccin
viru
molecular
structur
biologist
suggest
way
interfer
viral
life
cycl
focu
review
figur
strategi
start
viru
identif
goe
genom
sequenc
hope
end
antivir
drug
drug
develop
remain
challeng
acceler
drug
discoveri
offer
genom
technolog
hope
enabl
signific
timet
cut
achiev
antivir
medicin
classic
antivir
strategi
use
treat
sar
patient
like
use
interferon
discuss
interest
reader
refer
review
includ
retrospect
summari
develop
antihiv
drug
follow
apprais
antisar
strategi
applic
rapid
develop
antivir
sarscov
resurfac
next
probabl
inevit
viral
threat
earli
sudden
increas
lifethreaten
opportunist
infect
kaposi
sarcoma
consid
rare
observ
among
homosexu
inject
drug
user
infect
attribut
acquir
immunodefici
syndrom
aid
two
year
extens
studi
pass
human
immunodefici
viru
hiv
identifi
etiolog
agent
addit
two
year
pass
complet
sequenc
genom
huge
effort
invest
develop
first
drug
treat
aid
patient
bore
fruit
record
speed
fda
approv
azidothymidin
azt
azt
nucleosid
analog
inhibit
viral
revers
transcriptas
enzym
essenti
hiv
replic
unfortun
isol
patient
show
decreas
sensit
six
month
azt
administr
find
isol
also
exhibit
crossresist
nucleosid
analog
rais
concern
azt
nucleosid
revers
transcriptas
inhibitor
still
sole
treatment
avail
almost
decad
next
import
mileston
develop
inhibitor
proteas
anoth
essenti
viral
enzym
nonnucleosid
revers
transcriptas
inhibitor
first
approv
respect
nucleosid
revers
transcriptas
inhibitor
discov
cell
cultur
screen
direct
toward
specif
class
chemic
agent
nonnucleosid
revers
transcriptas
inhibitor
discov
ht
larg
compound
librari
discoveri
hiv
proteas
inhibitor
repres
one
best
exampl
applic
protein
structur
knowledg
ration
drug
design
sinc
aid
patient
treat
cocktail
inhibitor
hiv
revers
transcriptas
proteas
howev
despit
unpreced
success
therapi
hiv
infect
hiv
continu
spread
caus
new
infect
everi
day
develop
world
websit
major
problem
current
aid
treatment
high
frequenc
hiv
mutat
result
drug
resist
thu
effort
made
develop
agent
address
yet
untarget
step
hiv
life
cycl
viralinduc
fusion
viral
host
cell
membran
acknowledg
sarscov
life
cycl
vulner
therapeut
intervent
sever
place
viru
bind
cellular
receptor
outsid
cell
block
interact
sarscov
cellular
receptor
prevent
viru
attach
host
cell
coreceptor
antagonist
prevent
initi
next
step
wwwdrugdiscoverytodaycom
use
drug
target
approv
hiv
fusion
inhibitor
enfuvirtid
fuzeon
unlik
hiv
drug
small
molecul
develop
viral
enzym
enfuvirtid
peptid
correspond
specif
segment
viral
envelop
protein
importantli
segment
directli
pinpoint
comput
sequenc
analysi
strategi
seem
promis
develop
antivir
therapeut
peptid
virus
possess
type
viral
fusion
protein
eg
measl
viru
respiratori
syncyti
viru
rsv
share
structur
motif
hiv
littl
known
viralinduc
membran
fusion
virus
share
motif
virus
divid
two
group
base
composit
outer
surfac
nonenvelop
virus
enclos
protein
shell
call
capsid
b
envelop
virus
surround
membran
stolen
last
host
order
infect
host
cell
inject
genet
materi
cell
envelop
virus
need
overcom
viral
cellular
membran
barrier
viral
entri
mani
envelop
virus
includ
sarscov
involv
two
major
step
first
virion
bind
receptor
local
surfac
host
cell
second
viral
membran
fuse
host
cell
membran
sarscov
spike
glycoprotein
respons
two
step
translat
larg
polypeptid
subsequ
cleav
produc
two
function
subunit
peripher
protein
bind
cellular
receptor
wherea
type
transmembran
protein
catalyz
membran
fusion
reaction
step
crucial
viral
infect
therefor
suggest
target
antivir
sinc
identif
cellular
receptor
hiv
sever
therapeut
agent
aim
inhibit
bind
hiv
suggest
unfortun
effort
yet
bear
fruit
major
difficulti
slow
develop
inhibitor
bind
includ
site
consist
larg
recess
pocket
ii
antibodi
bind
antigen
like
block
viru
attach
immunosuppress
lead
deplet
cell
current
recombin
fusion
protein
smallmolecul
aim
prevent
hiv
attach
clinic
trial
effort
reflect
motiv
inhibit
first
step
viral
life
cycl
bind
viru
host
cell
approach
strengthen
identifi
addit
essenti
cellular
receptor
hiv
discoveri
peopl
resist
infect
hiv
similar
hiv
bind
viral
spike
glycoprotein
receptor
host
cell
first
step
sarscov
infect
block
interact
receptor
viru
could
prevent
infect
thu
inspir
search
sarscov
cellular
receptor
recent
human
angiotensin
convert
enzymerel
carboxypeptidas
type
integr
membran
metalloproteas
identifi
receptor
sarscov
solubl
form
antibodi
recogn
sarscov
effici
neutral
sarscov
vitro
support
specul
site
spike
glycoprotein
attract
target
vaccin
drug
develop
support
inhibitor
also
inhibit
sarscov
infect
vitro
notabl
acid
fragment
sarscov
effici
bound
block
spike
glycoproteinmedi
infect
ic
less
nm
recent
human
lung
cdna
librari
screen
identifi
receptor
sarscov
reveal
human
also
mediat
infect
sarscov
although
much
less
effici
receptor
interestingli
express
human
lung
type
ii
alveolar
cell
import
target
sarscov
infect
still
known
whether
interact
play
role
sarscov
infect
pathogenesi
hiv
entri
involv
bind
viral
envelop
glycoprotein
compris
homolog
sarscov
respect
host
cell
plasma
membran
induc
conform
chang
enabl
ntermin
heptad
repeat
region
nhr
expos
stage
enfuvirtid
bind
nhr
henc
block
conform
chang
requir
membran
fusion
enfuvirtid
synthet
peptid
inhibitor
correspond
segment
known
ctermin
heptad
repeat
chr
follow
conform
chang
plasma
membran
molecul
recruit
bind
site
bind
complex
trigger
highli
stabl
interact
chr
nhr
region
drive
membran
fusion
reaction
complet
thu
enfuvirtid
longer
inhibit
fusion
process
slower
engag
coreceptor
complex
result
stronger
inhibit
chrderiv
peptid
furthermor
reduct
bind
effici
result
slower
fusion
kinet
increas
sensit
enfuvirtid
support
model
provid
find
antagonist
show
strong
antihiv
synergi
enfuvirtid
hiv
isol
respect
addit
act
concert
enfuvirtid
viruscel
cellcel
fusion
assay
trigger
format
peptid
fusion
inhibitor
influenza
viru
noteworthi
influenza
viru
use
differ
mechan
enter
host
cell
first
endocytos
cell
follow
phdepend
fusion
viral
endosom
membran
strikingli
take
millisecond
time
ph
drop
endosom
fusion
process
complet
contrast
time
scale
hiv
infect
minut
allow
ampl
time
bind
entri
inhibitor
sarscov
entri
kinet
resembl
hiv
minut
exposur
sarscov
line
plasma
membran
vero
cell
fusion
entri
viral
load
cytoplasm
observ
mainli
minut
timescal
similar
hiv
sarscov
fusion
process
oppos
fast
membran
fusion
influenza
viru
indic
entri
inhibitor
could
success
sarscov
despit
lack
sequenc
similar
fusion
protein
sarscov
schemat
illustr
b
equival
protein
sarscov
leucineisoleucin
heptad
repeat
adjac
nterminu
protein
appear
redth
chr
green
cystein
residu
purpl
confin
loop
structur
locat
two
heptad
repeat
aromat
residuesrich
motif
mark
blue
transmembran
segment
orang
peptid
correspond
chr
act
potent
inhibitor
entri
cell
appear
yellowth
helic
wheel
top
view
singl
strand
coil
coil
wheel
project
nhr
c
chr
sarscov
protein
seven
posit
ag
correspond
locat
amino
acid
residu
make
coil
coilth
arrow
seven
posit
indic
rel
locat
adjac
residu
amino
acid
subsequenceth
helic
wheel
demonstr
potenti
antivir
drug
discov
base
sole
sequenc
inform
homolog
differ
length
sarscov
hiv
homolog
region
nhr
chr
sarscov
identifi
immedi
sarscov
genom
sequenc
publish
figur
thu
similar
strategi
might
appli
inhibit
entri
sarscov
http
wwwvirologynetarticl
inde
preliminari
report
reveal
antisar
activ
peptid
correspond
chr
sarscov
protein
indic
mode
action
similar
enfuvirtid
kinet
similar
sarscov
hiv
entri
suggest
synerg
sarscov
spike
glycoprotein
inhibitor
agent
block
receptor
role
differ
cellular
receptor
sarscov
entri
character
discov
receptor
trigger
conform
chang
transform
spike
protein
stabl
fusogen
form
antagonist
receptor
could
synerg
fusion
inhibitor
synergi
sar
fusion
inhibitor
antagonist
yet
investig
first
step
determin
optim
fusion
inhibitor
intriguingli
wherea
polar
residu
disrupt
heptad
repeat
chr
chr
sarscov
perfect
leucineisoleucin
heptad
repeat
figur
could
explain
exact
sequenc
boundari
chrderiv
peptid
crucial
effici
inhibit
aggreg
peptid
solut
could
abolish
antivir
activ
interestingli
two
report
demonstr
nhrderiv
peptid
also
activ
other
found
chrderiv
peptid
antisar
activ
noteworthi
reason
poor
inhibitori
activ
nhrderiv
peptid
virus
contribut
tendenc
aggreg
solut
suggest
similar
chrderiv
peptid
exact
sequenc
boundari
nhrderiv
peptid
import
main
advantag
fusion
inhibitor
immedi
discoveri
simpli
correspond
fragment
known
protein
howev
drawback
therapeut
peptid
lack
oral
bioavail
high
product
cost
auspici
sar
respiratori
syndrom
thu
peptid
fusion
inhibitor
could
given
inhal
approach
appli
success
rsvinfect
mice
serv
drug
target
viral
protein
fulfil
two
criteria
essenti
viral
life
cycl
ii
exhibit
low
similar
host
protein
sarscov
genom
analysi
perform
predict
proteom
three
viral
enzym
suggest
target
drug
discoveri
helicas
rnadepend
rna
polymeras
main
proteas
enzym
crucial
replic
transcript
translat
posttransl
polyprotein
process
box
assay
develop
base
three
sarscov
target
enzym
initi
thu
pave
way
highthroughput
vitro
screen
approach
identifi
candid
inhibitor
compound
librari
tradit
mani
case
costeffici
way
deal
virus
vaccin
logic
vaccin
develop
sarscov
emerg
combin
sever
find
reinfect
sarscov
caus
mild
ill
ii
sar
fatal
mainli
old
peopl
difficulti
produc
good
humor
cellular
immun
respons
iii
case
fatal
ratio
sar
rang
depend
age
group
affect
overal
review
box
current
inhibitor
target
three
enzym
crucial
sarscov
life
cycl
helicas
proteinfold
recognit
method
follow
biochem
studi
suggest
dual
use
sarscov
helicas
rna
synthesi
cap
format
suggest
new
avenu
treat
viru
screen
compound
librari
plaqu
reduct
assay
result
helicas
inhibitor
low
microm
rang
vitro
assay
confirm
sarscov
helicas
valid
drug
target
rnadepend
rna
polymeras
molecular
model
reveal
sarscov
rnadepend
rna
polymeras
contain
hydrophob
pocket
nonnucleosid
inhibitorsthi
contrast
nonnucleosid
inhibitor
activ
revers
transcriptas
mani
nucleosid
analogu
screen
sarscov
select
nucleosid
analogu
inhibitor
albeit
low
efficaci
microm
viru
yield
reduct
assay
ribavirin
broadspectrum
nucleosid
analogu
efficaci
treatment
sever
viral
infect
use
variou
countri
sarscovwhil
ribavirin
promis
vitro
recent
report
reveal
ribavirin
appear
confer
benefit
patient
sar
main
proteas
sequenc
similar
found
substratebind
site
sarscov
main
proteas
main
proteas
relat
virus
remark
sarscov
main
proteas
cleav
porcin
coronaviru
transmiss
gastroenter
coronaviru
tgev
main
proteas
substrat
ration
screen
known
proteas
inhibitor
antisar
activitythi
approach
reinforc
crystal
sarscov
main
proteas
togeth
tgev
inhibitor
find
reveal
homolog
model
often
inadequ
predict
mutual
orient
domain
multidomain
protein
howev
tgevbas
homolog
model
also
show
reason
model
substratebind
site
serv
develop
use
idea
inhibitor
design
inspir
medicin
chemist
start
synthesi
program
long
structur
target
enzym
experiment
determin
review
parallel
ht
compound
librari
identifi
inhibitor
sarscov
main
proteas
low
rang
studi
demonstr
inhibitor
hiv
proteas
also
inhibit
sarscov
albeit
much
lower
effici
wwwdrugdiscoverytodaycom
estim
case
fatal
websit
thu
infect
individu
recov
sar
furthermor
success
vaccin
mammalinfect
coronavirus
encourag
modern
antivir
vaccin
develop
depend
heavili
viral
genom
avail
human
genom
togeth
recent
sequenc
sarscov
genom
larg
increas
probabl
success
vaccin
develop
fulllength
spike
glycoprotein
sarscov
express
vaccinia
viru
induc
bind
neutral
antibodi
protect
immun
mice
subsequ
infect
sarscov
addit
dna
vaccin
encod
spike
glycoprotein
sarscov
induc
tcell
neutral
antibodi
respons
well
protect
immun
mous
model
discoveri
rnai
rais
mani
hope
regard
antivir
strategi
carri
promis
shortcut
drug
discoveri
process
usual
target
discoveri
follow
exhaust
ht
andor
structurebas
screen
mani
thousand
compound
hope
effici
bind
target
theoret
smallinterf
rna
sirna
drug
cours
target
drug
much
shorter
encourag
result
mice
obtain
use
rnaibas
therapi
hepat
b
viru
hbv
transfect
plasmid
express
short
hairpin
rna
shrna
homolog
hbv
mrna
effect
inhibit
replic
initi
cultur
cell
mice
liver
show
approach
could
use
treatment
viral
diseas
current
attempt
use
sirna
antisar
drug
still
preliminari
vitro
stage
applic
rel
new
technolog
therapeut
face
sever
safeti
technic
issu
includ
deliveri
rna
molecul
virusinfect
cell
activ
interferon
system
sarscov
remind
us
viral
infect
global
threat
vital
scientif
commun
acquir
abil
develop
antivir
therapi
promptli
encourag
remark
speed
global
commun
act
coordin
research
effort
investig
sarscov
immedi
last
nucleotid
sarscov
genom
verifi
sequenc
distribut
internet
worldwid
scientif
commun
among
genomicbas
approach
follow
inhibitor
viralinduc
membran
fusion
seem
promis
mutat
rate
sarscov
much
slower
among
lowest
rna
virus
howev
viral
resist
obstacl
solut
could
lie
use
drug
cocktail
combin
antivir
drug
differ
mode
action
eg
proteas
polymeras
inhibitor
lower
chanc
drugresist
virus
aris
addit
drug
cocktail
benefici
optim
dose
drug
given
monotherapi
toxic
combin
drug
distinct
mode
action
suboptim
dose
might
allevi
toxic
issu
moreov
recent
advanc
understand
hiv
entri
host
cell
reveal
opportun
synerg
base
molecular
mechan
viral
entri
drug
inhibit
interact
complex
enhanc
effici
hiv
fusion
inhibitor
elong
exposur
time
target
site
timescal
similar
sarscov
fusion
process
hiv
encourag
hope
futur
identif
character
sarscov
receptor
open
way
effici
antivir
strategi
synergist
combin
viral
entri
inhibitor
within
month
scientist
manag
leverag
technolog
advanc
past
year
antiaid
research
unpreced
antivir
campaign
sar
figur
sar
serv
test
tube
novel
approach
develop
follow
aid
epidem
current
sar
epidem
final
contain
yet
quick
develop
antivir
still
high
prioriti
today
closer
ever
achiev
therapeut
solut
viral
epidem
shortli
viral
outbreak
time
line
compar
key
achiev
aid
sar
research
effect
intern
collabor
technolog
advanc
greatli
acceler
understand
viral
diseas
anticip
research
achiev
also
lead
faster
drug
discoveri
develop
